Using small molecules to target and degrade specific RNAs in cancer cells
Targeted degradation of RNAs by using small molecules
This study is exploring a new way to help fight tough cancers, like Burkitt's lymphoma and triple-negative breast cancer, by using special small molecules that can target and break down harmful RNA in cancer cells, with the hope of creating better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-11141454 on NIH RePORTER |
What this research studies
This research focuses on developing a novel approach to selectively cleave and degrade specific RNA molecules in cancer cells using small molecules. By engineering compounds known as ribonuclease targeting chimeras (RiboTACs), the study aims to activate natural cellular enzymes that can target and destroy harmful RNA, particularly those associated with aggressive cancers like Burkitt's lymphoma and triple-negative breast cancer. The research involves testing these small molecules in both cell cultures and animal models to validate their effectiveness and safety. If successful, this approach could provide a new therapeutic strategy for patients with difficult-to-treat cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with aggressive cancers such as Burkitt's lymphoma, triple-negative breast cancer, or multiple myeloma.
Not a fit: Patients with non-cancerous conditions or those with cancers that do not involve the targeted RNA pathways may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments for patients with aggressive cancers by effectively targeting and degrading oncogenic RNAs.
How similar studies have performed: Previous studies have shown promising results with similar approaches using antisense oligonucleotides, indicating potential for success with this novel method.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Disney, Matthew D — University of Florida
- Study coordinator: Disney, Matthew D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.